Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07046000

MRI Evaluation of Graft Maturation Following ACL Reconstruction

Post-surgical ACL Graft maturation will be assessed at 4.5, 6, 7.5, 9, 10.5, and 12 months with MRI.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

14 year–50 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ACL tear and reconstruction; no other knee ligaments needing reconstruction
  • Primary (first-time) ACL tear in the affected knee
  • ACL injury occurred less than 12 months before ACL reconstruction
  • Have no contraindications or allergies to the treatment administered
  • Have current imaging studies (plain radiographs and MRI exams within the past 12 months) of the knee to rule out other etiologic diagnoses
  • Patient underwent ACL reconstruction with a Bone-Patellar Tendon-Bone (BTB) graft harvested from the same knee (ipsilateral autograft) with the Active Matrix tissue
  • Able and willing to comply with the post-operative study follow-up schedule

Exclusion criteria

  • Prior surgery on the index knee within 12 months of enrollment
  • Steroid injection into the index knee within 6 weeks of enrollment
  • Chronic ACL tear whereas the injury occurred more than 12 months ago
  • Multiligamentous injuries whereas any ligament (MCL, PCL, or PLC) in addition to the ACL needs to be reconstructed
  • Patient underwent ACL reconstruction with a hamstring tendon, Achilles tendon or quadriceps tendon graft (any graft other than a patellar tendon BTB)
  • Contraindication to MRI (eg, implanted devices incompatible with MRI).
  • Chrondral lesion of the knee that requires treatment during ACL reconstruction surgery
  • History of advanced osteoarthritis of the knee or patella-femoral joint; KL grade III or higher
  • History of malignant tumor and osseous metastatic disease,
  • History of chronic pain disorders (i.e., fibromyalgia),
  • Current substance abuse (drug or alcohol), by the investigator's judgment,
  • Females who are pregnant, nursing or breastfeeding, or who intend to become pregnant during participation in the study.
  • Currently participating in, or have been recently exited from (within 30 days from enrollment in this study), or plan to enroll in another clinical study for a bone allograft or drug that may impact participation or outcomes of this study,
  • Currently involved in any injury litigation or workers compensation claims,
  • Has a condition, disorder or other factor that, in the investigator's opinion, would interfere with study participation.

Treatment and study plan

MRI

Diagnostic Test

MRI to assess graft maturation

Primary outcomes

  1. Graft Maturation via MRI

    Time frame: From 4.5 months post surgery until 12 months or graft maturation.

    The signal to noise ratio will be calculated at the proximal, mid-substance, and distal positions of the graft

Study contacts

Contact information is provided by the study sponsor or research team.

Kyle Borque, MD

CONTACT

[email protected]

281-690-4678

Sponsors and collaborators

Lead sponsor

Skye Biologics Holdings, LLC

Industry

Registry information

Official study title

Magnetic Resonance Imaging (MRI) Evaluation of Graft Maturation Following Anterior Cruciate Ligament (ACL) Reconstruction With a Connective Tissue Allograft

Important dates

Study start
2026
Primary completion
2027
Study completion
2028
First posted
Jul 1, 2025
Registry last updated
Apr 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.